
Newsletter – September 15th 2022
In Vitro Testing of Dry Powder Nasal Delivery Devices Successful nasal drug delivery of dry powder formulations requires a delivered dose that can penetrate beyond
Upperton Pharma Solutions is an early phase Pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with more than twenty years of experience in the development of pharmaceutical dosage forms.
We offer our clients an extensive range of services, from early feasibility to dosage form development and clinical trial manufacturing.
Upperton’s formulation development team will confidently guide you on the best route forward.
Utilise our expertise and know-how to solve problems unique to your challenging molecule.
FIH through to phase II clinical
manufacturing. No project is too small or too challenging.
In Vitro Testing of Dry Powder Nasal Delivery Devices Successful nasal drug delivery of dry powder formulations requires a delivered dose that can penetrate beyond
Latest News from Upperton Pharma Solutions Successful MHRA Inspection Upperton is delighted to announce that during the last week of July 2022 the UK MHRA
Characterising the physical properties of spray dried powders The benefits of powder characterisation When developing products containing spray dried powders it is vital that the
Albert Einstein Centre, Nottingham Science Park, Nottingham, UK NG7 2TN,
Phone: +44 (0) 115 855 7050
Email: contact@upperton.com